Moreover, the suppression of FOXO3 expression confers sorafenib resistance to HCC cells by accelerating autophagy [33], whereas the inhibition of autophagy enhanced the sensitivity to sorafenib [34]. Here, FOXO3 is linked to hepatocellular carcinoma.